Publications by authors named "Vicente Abril Lopez de Medrano"
Article Synopsis
- Ceftobiprole medocaril (Cefto-M) is a fifth-generation antibiotic approved in Europe for pneumonia treatment, and a study was conducted in Spain to evaluate its use in clinical practice from September 2021 to December 2022.
- The study included 249 patients, mostly older adults with various infections, with respiratory infections being the most common; 67.9% received Cefto-M as empirical treatment, typically as monotherapy for about one week.
- The results showed an 11.2% infection-related mortality, with higher rates in patients with severe conditions like ventilator-associated pneumonia and sepsis, indicating that Cefto-M is generally safe and often used as a last-resort option
Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode of infection treated with vancomycin.
JAC Antimicrob Resist
April 2023
Objectives: To investigate the role of previous antibiotic therapy in the risk of recurrence after a infection (CDI) treated with vancomycin.
Methods: Multicentre observational study. Patients with a CDI episode achieving clinical cure with oral vancomycin and followed up 8 weeks were included.
Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study).
J Antimicrob Chemother
April 2022
Article Synopsis
- Ceftazidime/avibactam has shown potential as an effective treatment for infections caused by carbapenemase-producing Enterobacterales (CPE), particularly for patients with higher INCREMENT-CPE scores.
- In a study of 339 patients, those treated with ceftazidime/avibactam had lower mortality rates compared to those receiving the best available therapy after 30 days.
- The results suggest that ceftazidime/avibactam not only improves survival but also aids in achieving better clinical and microbiological outcomes, indicating the need for further randomized controlled trials to validate these findings.
The multi-resistant yeast has become a global public health threat because of its ease to persist and spread in clinical environments, especially in intensive care units. One of the most severe manifestations of invasive candidiasis is candidaemia, whose epidemiology has evolved to more resistant non- species, such as . It is crucial to establish infection control policies in order to control an outbreak due to nosocomial pathogens, including the implementation of screening colonisation studies.
View Article and Find Full Text PDF